NOT KNOWN FACTUAL STATEMENTS ABOUT OXY HEALTH CHAMBER

Look at Total Prescribing Data OPDIVO® (nivolumab) is indicated for your treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed right after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or right after 3 or more traces of systemic therapy that features autologous HSCT.